Italia markets closed

Ipsen S.A. (0MH6.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
92,89-0,06 (-0,06%)
Alla chiusura: 05:19PM GMT

Ipsen S.A.

65 Quai Georges Gorse
Boulogne-Billancourt 92100
33 1 58 33 50 00

Impiegati a tempo pieno4.500

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. David LoewMD, CEO & Director2,3MN/D1967
Mr. Aymeric Le ChatelierExec. VP & Group CFON/DN/D1969
Dr. Aidan Murphy Ph.D.Exec. VP of Technical OperationsN/DN/D1966
Mr. Craig MarksVice-Pres of Investor RelationsN/DN/DN/D
Mr. Francois GarnierExec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics OfficerN/DN/D1962
Ms. Gwenan WhiteExec. VP of Communications & Public AffairsN/DN/DN/D
Mr. Regis MulotExec. VP & Chief HR OfficerN/DN/D1966
Mr. Stephan GagneHead of New Tokyo OfficeN/DN/DN/D
Ms. Dominique BeryHead of Nordics & BalticsN/DN/D1971
Dr. Yan Moore M.D.Sr. VP & Head of Oncology Therapeutic AreaN/DN/D1967
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.


Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Governance aziendale

L'ISS Governance QualityScore di Ipsen S.A. al 1 febbraio 2023 è 9. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 9; diritti degli azionisti: 7; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.